Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis

International Journal of Antimicrobial Agents

Volumn 51, Issue 1, 2018, Pages 1-9

  Vardakas, Konstantinos Z ^a,b   Voulgaris, Georgios L ^a,c   Samonis, George ^d   Falagas, Matthew E ^a,b,d,e  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c 401 GENERAL MILITARY HOSPITAL OF ATHENS   (Greece)

^d UNIVERSITY OF CRETE   (Greece)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aerosolized; Colistimethate sodium; Klebsiella pneumoniae; Nebulizer; Nephrotoxicity

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOPERAZONE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; MONOBACTAM DERIVATIVE; POLYMYXIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACUTE KIDNEY FAILURE; ADULT; APACHE; ARGENTINA; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CREATININE CLEARANCE; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENTEROBACTERIACEAE; FEMALE; FRANCE; GREECE; HOSPITAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; KOREA; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MONOTHERAPY; MOROCCO; MORTALITY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUROTOXICITY; NOSOCOMIAL PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RENAL REPLACEMENT THERAPY; RESPIRATORY TRACT INFECTION; REVIEW; SINGAPORE; STENOTROPHOMONAS MALTOPHILIA; SYSTEMATIC REVIEW; TAIWAN; THAILAND; TRACHEOBRONCHITIS; TREATMENT DURATION; TUNISIA; VENTILATOR ASSOCIATED PNEUMONIA; ACINETOBACTER INFECTION; DRUG EFFECT; INHALATIONAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTION; MICROBIOLOGY; NEBULIZER; PSEUDOMONAS INFECTION; TREATMENT OUTCOME;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; NEBULIZERS AND VAPORIZERS; PNEUMONIA, VENTILATOR-ASSOCIATED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME;

EID: 85039951281     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2017.05.016     Document Type: Review

References (50)

1. Kollef, K.E., Schramm, G.E., Wills, A.R., Reichley, R.M., Micek, S.T., Kollef, M.H., Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 134 (2008), 281–287.
2. Peleg, A.Y., Hooper, D.C., Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 362 (2010), 1804–1813.
3. Siempos, I.I., Vardakas, K.Z., Kyriakopoulos, C.E., Ntaidou, T.K., Falagas, M.E., Predictors of mortality in adult patients with ventilator-associated pneumonia: a meta-analysis. Shock 33 (2010), 590–601.
4. Falagas, M.E., Kopterides, P., Old antibiotics for infections in critically ill patients. Curr Opin Crit Care 13 (2007), 592–597.
5. Vardakas, K.Z., Rafailidis, P.I., Konstantelias, A.A., Falagas, M.E., Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug?. J Infect 66 (2013), 401–414.
6. Biswas, S., Brunel, J.M., Dubus, J.C., Reynaud-Gaubert, M., Rolain, J.M., Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther 10 (2012), 917–934.
7. Rodvold, K.A., Yoo, L., George, J.M., Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents. Clin Pharmacokinet 50 (2011), 689–704.
8. Rottboll, L.A., Friis, C., Penetration of antimicrobials to pulmonary epithelial lining fluid and muscle and impact of drug physicochemical properties determined by microdialysis. J Pharmacol Toxicol Methods 78 (2016), 58–65.
9. Palmer, L.B., Aerosolized antibiotics in critically ill ventilated patients. Curr Opin Crit Care 15 (2009), 413–418.
10. Kalin, G., Alp, E., Coskun, R., Demiraslan, H., Gundogan, K., Doganay, M., Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment?. J Infect Chemother 18 (2012), 872–877.
11. Kofteridis, D.P., Alexopoulou, C., Valachis, A., Maraki, S., Dimopoulou, D., Georgopoulos, D., et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis 51 (2010), 1238–1244.
12. Korbila, I.P., Michalopoulos, A., Rafailidis, P.I., Nikita, D., Samonis, G., Falagas, M.E., Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect 16 (2010), 1230–1236.
13. Tumbarello, M., De Pascale, G., Trecarichi, E.M., De Martino, S., Bello, G., Maviglia, R., et al. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. Chest 144 (2013), 1768–1775.
14. Liu, D., Zhang, J., Liu, H.X., Zhu, Y.G., Qu, J.M., Intravenous combined with aerosolised polymyxin versus intravenous polymyxin alone in the treatment of pneumonia caused by multidrug-resistant pathogens: a systematic review and meta-analysis. Int J Antimicrob Agents 46 (2015), 603–609.
15. Valachis, A., Samonis, G., Kofteridis, D.P., The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis. Crit Care Med 43 (2015), 527–533.
16. Kalil, A.C., Metersky, M.L., Klompas, M., Muscedere, J., Sweeney, D.A., Palmer, L.B., et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 63 (2016), 575–582.
17. Athanassa, Z.E., Markantonis, S.L., Fousteri, M.Z., Myrianthefs, P.M., Boutzouka, E.G., Tsakris, A., et al. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med 38 (2012), 1779–1786.
18. Boisson, M., Jacobs, M., Gregoire, N., Gobin, P., Marchand, S., Couet, W., et al. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother 58 (2014), 7331–7339.
19. Abdellatif, S., Trifi, A., Daly, F., Mahjoub, K., Nasri, R., Ben Lakhal, S., Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial. Ann Intensive Care, 6, 2016, 26.
20. Chen, Y.M., Fang, W.F., Kao, H.C., Chen, H.C., Tsai, Y.C., Shen, L.S., et al. Influencing factors of successful eradication of multidrug-resistant Acinetobacter baumannii in the respiratory tract with aerosolized colistin. Biomed J 37 (2014), 314–320.
21. Choi, H.K., Kim, Y.K., Kim, H.Y., Uh, Y., Inhaled colistin for treatment of pneumonia due to colistin-only-susceptible Acinetobacter baumannii. Yonsei Med J 55 (2014), 118–125.
22. Hsieh, T.C., Chen, F.L., Ou, T.Y., Jean, S.S., Lee, W.S., Role of aerosolized colistin methanesulfonate therapy for extensively-drug-resistant Acinetobacter baumannii complex pneumonia and airway colonization. J Microbiol Immunol Infect 49 (2016), 523–530.
23. Kuo, S.C., Lee, Y.T., Yang, S.P., Chen, C.P., Chen, T.L., Hsieh, S.L., et al. Eradication of multidrug-resistant Acinetobacter baumannii from the respiratory tract with inhaled colistin methanesulfonate: a matched case-control study. Clin Microbiol Infect 18 (2012), 870–876.
24. Kwa, A.L., Loh, C., Low, J.G., Kurup, A., Tam, V.H., Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 41 (2005), 754–757.
25. Lin, C.C., Liu, T.C., Kuo, C.F., Liu, C.P., Lee, C.M., Aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii pneumonia: experience in a tertiary care hospital in northern Taiwan. J Microbiol Immunol Infect 43 (2010), 323–331.
26. Lu, Q., Luo, R., Bodin, L., Yang, J., Zahr, N., Aubry, A., et al. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology 117 (2012), 1335–1347.
27. Maskin, L.P., Setten, M., Rodriguez, P.O., Bonelli, I., Attie, S., Stryjewski, M.E., et al. Inhaled colistimethate sodium in ventilator-associated tracheobronchitis due to multidrug-resistant Gram-negative bacteria. Int J Antimicrob Agents 45 (2015), 199–200.
28. Motaouakkil, S., Charra, B., Hachimi, A., Nejmi, H., Benslama, A., Elmdaghri, N., et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 53 (2006), 274–278.
29. Rattanaumpawan, P., Lorsutthitham, J., Ungprasert, P., Angkasekwinai, N., Thamlikitkul, V., Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 65 (2010), 2645–2649.
30. Imberti, R., Cusato, M., Villani, P., Carnevale, L., Iotti, G.A., Langer, M., et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest 138 (2010), 1333–1339.
31. Lu, Q., Girardi, C., Zhang, M., Bouhemad, B., Louchahi, K., Petitjean, O., et al. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med 36 (2010), 1147–1155.
32. Markou, N., Fousteri, M., Markantonis, S.L., Boutzouka, E., Tsigou, E., Baltopoulo, G., Colistin penetration in the alveolar lining fluid of critically ill patients treated with IV colistimethate sodium. Chest 139 (2011), 232–233 author reply 233–4.
33. Vardakas, K.Z., Rellos, K., Triarides, N.A., Falagas, M.E., Colistin loading dose: evaluation of the published pharmacokinetic and clinical data. Int J Antimicrob Agents 48 (2016), 475–484.
34. Gontijo, A.V., Gregoire, N., Lamarche, I., Gobin, P., Couet, W., Marchand, S., Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 2. Colistin. Antimicrob Agents Chemother 58 (2014), 3950–3956.
35. Dickinson, J.D., Kollef, M.H., Early and adequate antibiotic therapy in the treatment of severe sepsis and septic shock. Curr Infect Dis Rep 13 (2011), 399–405.
36. Choi, I.S., Lee, Y.J., Wi, Y.M., Kwan, B.S., Jung, K.H., Hong, W.P., et al. Predictors of mortality in patients with extensively drug-resistant Acinetobacter baumannii pneumonia receiving colistin therapy. Int J Antimicrob Agents 48 (2016), 175–180.
37. Iregui, M., Ward, S., Sherman, G., Fraser, V.J., Kollef, M.H., Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 122 (2002), 262–268.
38. Luna, C.M., Aruj, P., Niederman, M.S., Garzon, J., Violi, D., Prignoni, A., et al. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J 27 (2006), 158–164.
39. Ari, A., Aerosol therapy in pulmonary critical care. Respir Care 60 (2015), 858–874 discussion 874–9.
40. Ari, A., Atalay, O.T., Harwood, R., Sheard, M.M., Aljamhan, E.A., Fink, J.B., Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation. Respir Care 55 (2010), 845–851.
41. Ari, A., Fink, J.B., Dhand, R., Inhalation therapy in patients receiving mechanical ventilation: an update. J Aerosol Med Pulm Drug Deliv 25 (2012), 319–332.
42. Bohr, A., Beck-Broichsitter, M., Generation of tailored aerosols for inhalative drug delivery employing recent vibrating-mesh nebulizer systems. Ther Deliv 6 (2015), 621–636.
43. Dolovich, M.B., Dhand, R., Aerosol drug delivery: developments in device design and clinical use. Lancet 377 (2011), 1032–1045.
44. Ibrahim, M., Verma, R., Garcia-Contreras, L., Inhalation drug delivery devices: technology update. Med Devices (Auckl) 8 (2015), 131–139.
45. Pitance, L., Vecellio, L., Leal, T., Reychler, G., Reychler, H., Liistro, G., Delivery efficacy of a vibrating mesh nebulizer and a jet nebulizer under different configurations. J Aerosol Med Pulm Drug Deliv 23 (2010), 389–396.
46. Dhand, R., Guntur, V.P., How best to deliver aerosol medications to mechanically ventilated patients. Clin Chest Med 29 (2008), 277–296 vi.
47. Ari, A., Fink, J.B., Differential medical aerosol device and interface selection in patients during spontaneous, conventional mechanical and noninvasive ventilation. J Aerosol Med Pulm Drug Deliv 29 (2016), 95–106.
48. Cikman, A., Gulhan, B., Aydin, M., Ceylan, M.R., Parlak, M., Karakecili, F., et al. In vitro Activity of colistin in combination with tigecycline against carbapenem-resistant Acinetobacter baumannii strains isolated from patients with ventilator-associated pneumonia. Int J Med Sci 12 (2015), 695–700.
49. Le Minh, V., Thi Khanh Nhu, N., Vinh Phat, V., Thompson, C., Huong Lan, N.P., Thieu Nga, T.V., et al. In vitro activity of colistin in antimicrobial combination against carbapenem-resistant Acinetobacter baumannii isolated from patients with ventilator-associated pneumonia in Vietnam. J Med Microbiol 64 (2015), 1162–1169.
50. Liu, X., Zhao, M., Chen, Y., Bian, X., Li, Y., Shi, J., et al. Synergistic killing by meropenem and colistin combination of carbapenem-resistant Acinetobacter baumannii isolates from Chinese patients in an in vitro pharmacokinetic/pharmacodynamic model. Int J Antimicrob Agents 48 (2016), 559–563.